article thumbnail

FDA Approves Nitisinone for Treatment of Alkaptonuria

Drug Topics

Patients were enrolled at the National Institutes of Health Clinical Center between April 2005 and March 2006, with 20 people receiving no treatment and 20 receiving nitisinone once daily. All patients were aged 18 to 65 years of age, except for 1 who was older than 65 years. Approximately 67.5%

FDA 307
article thumbnail

Progress in Dermatology Paves the Way for Vaccine Development

Drug Topics

2 With the chickenpox vaccine being one of the first available for prevention of skin disease in 1995, 3 the shingles vaccine was later approved in 2006 4 and the mpox was approved much later in 2019. 5 Throughout the past 10 years, development of vaccines for preventing skin diseases has made significant progress.

Vaccines 247
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties

STAT

Krystal, who worked for both Yale and the VA at the time, and his co-inventors applied for patents with VA funding starting in 2006 for a ketamine nasal spray to treat depression and suicidal ideation. Yale and the VA agreed in 2003 to share royalties on patents with inventors from both institutions.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1

article thumbnail

From Healing to Harm: The Unintended Consequences of Polypharmacy in Seniors

PharmD Live

The side effects can compound, resulting in a greater negative impact on a patient’s health than the individual effects of one medication alone. Institute of Medicine, 2006). Adverse Drug Reactions (ADRs) Adverse drug reactions are a major concern in polypharmacy. million people annually in the U.S. Preventing Medication Errors.

Hospitals 119
article thumbnail

Can you use montelukast for allergies? [ANSWERED]

Druggist

It is recommended to use montelukast as a secondary option in treating allergic rhinitis, preferably in combination with an antihistamine (Grainger & Drake-Lee, 2006). As the name suggests, anti histamines reduce the actions of histamine, which is the leading compound (mediator) released by cells contributing to symptoms of allergies.